Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Japanese Patients with Active Rheumatoid Arthritis
NCT02373202Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sarilumab in rheumatoid arthritis (RA) (4 arms), sponsored by Sanofi. Primary endpoints: Treatment-Emergent Adverse Events and Serious Adverse Events at 58 weeks, Potentially Clinically Significant Vital Signs Abnormalities at 58 weeks and 2 more. Started Feb 2015; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02373202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02373202.